16. Juni 2026

Walder Wyss acted as Swiss legal advisor to VERAXA Biotech AG (“VERAXA”) in connection with VERAXA’s successful business combination with Voyager Acquisition Corp. and its listing on the NASDAQ Stock Market on 11 June 2026 under the ticker symbols “VRXA” and “VRXAW”.

Through this transaction, VERAXA strengthened its financial position, including through a USD 27.5 million senior secured note financing and a share purchase agreement for up to USD 50 million. The proceeds will be used to further advance VERAXA’s oncology pipeline based on its proprietary BiTAC platform, supporting progress towards clinical development and industry partnerships. The successful stock market listing represents a significant milestone for VERAXA to be on the forefront of the next generation of antibody-based cancer therapeutics.

The Walder Wyss team was led by Marius Breier (Partner, Tax) and Thiemo Sturny (Partner, Corporate/M&A) and included Martina Madonna-Quadri (Senior Associate, Corporate/M&A), Stefan Walder (Counsel, Corporate/M&A), Manu Ferro (Senior Associate, Banking & Finance), Dimitrios Berger (Managing Associate, Corporate/M&A), Christian A. Schmid (Managing Associate, Corporate/M&A), Maurus Winzap (Partner, Tax), and Nicolas Bopp (Associate/Tax) advising on all relevant Swiss tax and legal aspects of the transaction and the listing.